MGMT PROMOTER METHYLATION

mgmt启动子甲基化已被观察到影响多形性胶质母细胞瘤的肿瘤进展。在出现启动子甲基化的患者中，Akylating试剂卡莫司汀已显示出疗效。在缺乏甲基化的患者中，卡莫司汀和MGMT抑制剂O（6）-苄基鸟嘌呤结合可能有效，但需要更多的实验。临床试验也显示启动子甲基化阳性患者对替莫唑胺的选择性敏感性，为GBM患者进行更广泛的甲基化筛选提供了依据。
MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.